Exosomes are small membrane-enclosed vesicles of endocytic origin approximately 30–150 nm in diameter. The lipid bilayer contains both transmembrane and non-membrane proteins and encloses a variety of molecules including non-coding RNAs, mRNAs, miRNAs, either single- stranded or double-stranded DNA and proteins . Exosomes are actively secreted by most cells, including primary or metastatic tumour cells, into biological fluids including serum, plasma, urine, breast milk, and saliva . Studies have found that the analysis of exosome-associated nucleic acids, proteins and/or lipids can indicate the presence of a range of cancers, including pancreatic cancer, colorectal cancer , breast cancer , and non-small cell lung cancer .
Therefore, exosomes represent an exciting new avenue of cancer diagnosis. As a group of promising biomarkers, the analysis of biomarkers associated with exosomes in blood may offer a minimally invasive route for cancer diagnosis and prognosis.
Extraction and isolation
Despite the explosion in exosome research and their potential in disease (especially cancer) diagnostics, exosome-associated biomarkers have not yet been translated to meet the rapid developments in molecular medicine for commercial liquid biopsy applications. This is primarily due to the limitations of current exosome capture and isolation methods such as ultracentrifugation, that are time consuming, operator dependent and not scalable.
Introducing EXO-NET™ for exosome capture (Research Use Only)
BARD1’s EXO-NET™ product allows for fast, accurate and efficient capture and isolation of exosomes from any liquid biopsy sample. The technology is highly scalable and is compatible with existing automated testing systems making it ideal for high volume clinical laboratory applications.
The EXO-NET™ matrix that is coated onto magnetic beads has the following features that make it a unique universal technology to facilitate the development of a range of exosome isolation applications:
EXO-NET beads demonstrate superior exosome capture ability in comparison to a commercial competitor, as evidenced by the concentration of known CD63 and CD9 exosome specific biomarkers. In addition to demonstrating outperformance compared to commercial products, EXO-NET for RUO demonstrates outperformance against ultra-centrifugation (the recognised research gold-standard method), in a fraction of the time (15 minutes versus 6-12 hours).
For more information, and for pricing and ordering, go to www.exo-net.com
 Mathai RA, Vidya RV, Reddy BS, et al. Potential utility of liquid biopsy as a diagnostic and prognostic tool forthe assessment of solid tumors: Implications in the precision oncology. J Clin Med 2019; 8(3):373
 Qi Z-H, Xu H-X, Shi-Rong Zhang S-R, Xu J-Z, et al. The significance of liquid biopsy in pancreatic cancer. J Cancer 2018; 9(18): 3417-3426. doi: 10.7150/jca.24591
 Chen Y, Xie Y, Xu L, et al. Protein content and functional characteristics of serum-purified exosomes from patients with colorectal cancer revealed by quantitative proteomics. Int J Cancer 2017; 140: 900–913
 Meng Y, Sun J, Wang X, et al. Exosomes: A promising avenue for the diagnosis of breast cancer. Technol Cancer Res Treat 2019; 18:1-14.
 Masaoutis C, Mihailidou C, Tsourouflis G, Theocharis S. Exosomes in lung cancer diagnosis and treatment. From the translating research into future clinical practice. Biochimie 2018; 151: 27-36. doi:10.1016/j.biochi.2018.05.014